Imatinib mesylate (imatinib) is a small molecular inhibitor of the tyrosine kinase activity of the BCR–ABL fusion protein, and is now a frontline therapy for CML [4]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.